Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device company focusing on sleep-related breathing disorders, has announced the release of its second quarter 2024 financial results after market close on August 14, 2024. The company will host a conference call at 5:00 pm ET on the same day to discuss the results and provide updates on recent achievements and developments.
Investors can access the call by dialing (800) 717-1738 (US) or (646) 307-1865 (international). A replay will be available until August 28, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international) with passcode 1157721. A live webcast and 30-day archive will be available on the company's investor relations website.
Vivos Therapeutics (NASDAQ: VVOS), un'azienda leader nel settore dei dispositivi medici focalizzata sui disturbi respiratori legati al sonno, ha annunciato il rilascio dei suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato il 14 agosto 2024. L'azienda terrà una conference call alle 17:00 ET dello stesso giorno per discutere i risultati e fornire aggiornamenti sulle conquiste e sviluppi recenti.
Gli investitori possono accedere alla chiamata componendo (800) 717-1738 (USA) o (646) 307-1865 (internazionale). Una registrazione sarà disponibile fino al 28 agosto 2024, accessibile componendo (844) 512-2921 (USA) o (412) 317-6671 (internazionale) con il codice di accesso 1157721. Un webcast in diretta e un archivio di 30 giorni saranno disponibili sul sito web per le relazioni con gli investitori dell'azienda.
Vivos Therapeutics (NASDAQ: VVOS), una empresa líder en dispositivos médicos enfocada en trastornos respiratorios relacionados con el sueño, ha anunciado el lanzamiento de sus resultados financieros del segundo trimestre de 2024 después del cierre del mercado el 14 de agosto de 2024. La empresa llevará a cabo una llamada en conferencia a las 5:00 pm ET el mismo día para discutir los resultados y proporcionar actualizaciones sobre logros y desarrollos recientes.
Los inversores pueden acceder a la llamada marcando (800) 717-1738 (EE. UU.) o (646) 307-1865 (internacional). Una repetición estará disponible hasta el 28 de agosto de 2024, accesible marcando (844) 512-2921 (EE. UU.) o (412) 317-6671 (internacional) con el código de acceso 1157721. Una transmisión web en vivo y un archivo de 30 días estarán disponibles en el sitio web de relaciones con inversores de la empresa.
비보스 테라퓨틱스 (NASDAQ: VVOS), 수면 관련 호흡 장애에 초점을 맞춘 선도적인 의료 기기 회사가 2024년 8월 14일 시장 마감 후 2024년 2분기 재무 실적 발표를 알렸습니다. 같은 날 동부 표준시 오후 5시에 결과를 논의하고 최근 성과 및 개발 사항을 제공하는 컨퍼런스 콜을 개최합니다.
투자자들은 (800) 717-1738 (미국) 또는 (646) 307-1865 (국제)로 전화하여 콜에 접속할 수 있습니다. 2024년 8월 28일까지 재생이 가능하며, (844) 512-2921 (미국) 또는 (412) 317-6671 (국제)로 전화하고 비밀번호 1157721로 접근할 수 있습니다. 회사의 투자자 관계 웹사이트에서 실시간 웹캐스트 및 30일 아카이브도 제공됩니다.
Vivos Therapeutics (NASDAQ: VVOS), une entreprise leader dans le domaine des dispositifs médicaux spécialisée dans les troubles respiratoires liés au sommeil, a annoncé la publication de ses résultats financiers du deuxième trimestre 2024 après la clôture du marché le 14 août 2024. L'entreprise tiendra une conférence téléphonique à 17h00 ET le même jour pour discuter des résultats et fournir des mises à jour sur les réalisations et développements récents.
Les investisseurs peuvent accéder à l'appel en composant le (800) 717-1738 (USA) ou le (646) 307-1865 (international). Un enregistrement sera disponible jusqu'au 28 août 2024, accessible en composant le (844) 512-2921 (USA) ou le (412) 317-6671 (international) avec le code d'accès 1157721. Un webcast en direct et un archive de 30 jours seront disponibles sur le site web des relations investisseurs de l'entreprise.
Vivos Therapeutics (NASDAQ: VVOS), ein führendes Unternehmen im Bereich medizinischer Geräte, das sich auf schlafbezogene Atemstörungen spezialisiert hat, hat die Veröffentlichung seiner finanziellen Ergebnisse für das zweite Quartal 2024 nach Börsenschluss am 14. August 2024 bekannt gegeben. Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Aktualisierungen zu kürzlichen Errungenschaften und Entwicklungen bereitzustellen.
Investoren können an der Konferenz teilnehmen, indem sie (800) 717-1738 (USA) oder (646) 307-1865 (international) wählen. Eine Wiederholung wird bis zum 28. August 2024 verfügbar sein, erreichbar unter (844) 512-2921 (USA) oder (412) 317-6671 (international) mit dem Zugangscode 1157721. Ein Live-Stream und ein 30-tägiges Archiv werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- Timely financial reporting with same-day conference call
- Provision of multiple access options for investors (phone and webcast)
- None.
Call Scheduled for Today, Wednesday, August 14, 2024 at 5:00 pm ET
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024.
Vivos’ management will conduct a conference call today at 5:00 p.m. (Eastern Time) to review the results and provide an overview of Vivos’ recent achievements and developments.
To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 1157721. The replay will be available until August 28, 2024.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution for treating mild to severe OSA. It has proven effective in over 45,000 patients treated worldwide by more than 2,000 trained dentists.
The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that alter the size, shape, and position of the jaws and soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual results of the initiatives described herein on Vivos’ future revenues and results of operations or the anticipated benefits of the Company’s new business model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all or maintain its Nasdaq listing and (v) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Vivos Investor Relations and Media Contact:
John Lee
EVP, Marketing
714-417-0317
jlee@vivoslife.com
FAQ
When will Vivos Therapeutics (VVOS) release its Q2 2024 financial results?
What time is the Vivos Therapeutics (VVOS) Q2 2024 earnings conference call?
How can investors access the Vivos Therapeutics (VVOS) Q2 2024 earnings call?
Until what date will the replay of Vivos Therapeutics (VVOS) Q2 2024 earnings call be available?
